HUMIRA
Google image searchProduct monograph
Active ingredient
adalimumab, 20 MG/0.2 ML
DIN: 02474263
Dosage form(s): SOLUTION
Route(s) of administration: SUBCUTANEOUS
Description: PREFILLED SYRINGE
Schedule: Prescription / Schedule D
Company: ABBVIE CORPORATION
Date: 18-AUG-2020
ATC:
- L04 — IMMUNOSUPPRESSANTS (ATC, ATC/DDD, )
- L04A — IMMUNOSUPPRESSANTS (ATC, ATC/DDD)
- L04AB — Tumor necrosis factor alpha (TNF-alpha) inhibitors (ATC, ATC/DDD)
- L04AB04 — ADALIMUMAB (ATC/DDD)
Reference brand drug: Humira
